Friday, October 31, 2014 Last update: 1:03 PM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

Updated Phase 2 Clinical Data on Tokai Pharmaceuticals’ Galeterone in Advanced Prostate Cancer to be Presented at the 2014 ASCO Annual Meeting

Companies mentioned in this article: Tokai Pharmaceuticals, Inc.

CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer and other hormonally driven cancers, today announced that updated results from its ongoing ARMOR2 Phase 2 study of its lead drug candidate, galeterone (TOK-001), in patients with castration-resistant prostate cancer (CRPC) will be presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

The details of the poster presentation are as follows:

Date & Time: Saturday, May 31, 2014 from 1:15 p.m. to 4:15 p.m. (CT)

Title: Galeterone in men with CRPC: Results in four distinct patient populations from the ARMOR2 study

Abstract Number: 5029

Session: Poster Highlights Session, Genitourinary Cancer Track

Poster Board: 44

Location: E354b

Presenter: Bruce Montgomery, M.D., associate professor of medical oncology at the University of Washington School of Medicine, and co-principal investigator of ARMOR2

Following the meeting, the poster presentation will be available on the Tokai website at www.tokaipharma.com.

About Galeterone

Galeterone (TOK-001), is a highly selective, multi-targeted, oral small molecule drug being developed for the treatment of castration-resistant prostate cancer (CRPC) that disrupts androgen receptor (AR) signaling, the key driver of CRPC, via multiple mechanisms of action. Galeterone combines the mechanisms of action of CYP17 inhibition and androgen receptor antagonism with that of androgen receptor degradation.

About Tokai Pharmaceuticals

Tokai Pharmaceuticals is a biopharmaceutical company focused on developing new treatments for prostate cancer and other hormonally driven diseases. The company’s lead drug candidate, galeterone (TOK-001), is a first-in-class, multi-targeted, oral small molecule drug being developed for the treatment of patients with castration-resistant prostate cancer (CRPC). Based in Cambridge, Massachusetts, Tokai is backed by Apple Tree Partners, Novartis Venture Fund and the Satter Foundation. For more information on the company and galeterone, please visit www.tokaipharma.com.


Copyright © Business Wire 2014
Contact:

Pure Communications
Sheryl Seapy, 949-903-4750
sheryl@purecommunicationsinc.com